Publication


Featured researches published by Mark Levis.


Archive | 2014

Treatment With Quizartinib (AC220) Enables a High Rate of Patients With Relapsed or Refractory FLT3-ITD(+) Acute Myeloid Leukemia to be Bridged to HSCT

Giovanni Martinelli; Mark Levis; Alexander E. Perl; Hervé Dombret; Björn Steffen; Philippe Rousselot; Elihu H. Estey; Neil P. Shah; Guy Gammon; Denise Trone; Jorge Cortes; Aml Progression


Blood | 2004

FLT3-Targeted Therapy Selectively Kills MLL-Rearranged Infant and Childhood ALL Blasts In Vitro and in Vivo.

Patrick O. Brown; Obdulio Piloto; Mark Levis; Sheila A. Shurtleff; Dario Campana; James R. Downing; Donald Small


Archive | 2014

myeloid leukemia cells in acute - CD38 + A clinically relevant population of leukemic CD34

Saul J. Sharkis; Michael J. Borowitz; Judith E. Karp; Steven Galkin; Michael I. Collector; Brandy Perkins; Mark Levis; Constance A. Griffin; Jonathan M. Gerber; B. Douglas Smith; Hao Zhang; Milada S. Vala


Archive | 2013

insights into the basis for cytotoxic response to FLT3 inhibitors Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals

Johannes Roesel; Judith E. Karp; Ilene Galinsky; Frank Giles; Elihu H. Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Mark Levis; Patrick O. Brown; B. Douglas Smith; Adam Stine; Rosalyn Pham


Archive | 2013

cyclophosphamide for adults with refractory acute leukemias A phase 1 clinical-laboratory study of clofarabine followed by

B. Douglas Smith; Michael A. McDevitt; Hetty E. Carraway; Mark Levis; Varsha Gandhi; Judith E. Karp; Rebecca M. Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer


Archive | 2013

leukemia clinical activity in patients with relapsed or refractory acute myeloid

Mark Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small; B. Douglas Smith; Mark Levis; Miloslav Beran; Francis J. Giles; Hagop Kantarjian; Karin D. Berg


Archive | 2013

fit for intensive chemotherapy treatment for older patients with acute myeloid leukemia not considered A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line

Richard E. Clark; Mark Levis; Donald Small; Steven Knapper; Alan K. Burnett; Tim Littlewood; W. Jonathan Kell; Sam Agrawal; Raj Chopra


Archive | 2012

followed by cytosine arabinoside and mitoxantrone for acute leukemias Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol

Michelle A. Rudek; Michael A. McDevitt; Karen Mackey; Janet Briel; L. Austin Doyle; Katrina Alino; Mark Levis; Steven D. Gore; Biju Joseph; E. Karp; B. Douglas Smith; Linda S. Resar; Jacqueline Greer; Amanda Blackford


Archive | 2010

cells with high levels of FLT3 expression FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia

Patrick O. Brown; Mark Levis; Sheila A. Shurtleff; Dario Campana; James R. Downing; Donald Small


Archive | 2010

of parallel signaling pathways Prolonged exposure to FLT3 inhibitors leads to resistance via activation

Obdulio Piloto; Patrick O. Brown; Kyu-Tae Kim; Mark Levis; Donald Small

Researchain Logo
Decentralizing Knowledge